Vitalhub (6OVA) Stock Price & Analysis
6OVA Stock Chart & Stats
- Day’s Range
- EUR 4.88 - EUR 4.96
- 52-Week Range
- EUR 4.00 - EUR 6.75
- Previous Close
- EUR 4.86
- Volume
- N/A
- Average Volume (3M)
- 61
- Market Cap
- EUR 316.03M
- Enterprise Value
- EUR 326.26M
- Total Cash (Recent Filing)
- EUR 136.51M
- Total Debt (Recent Filing)
- EUR 2.86M
- Price to Earnings (P/E)
- 65.3
- Beta
- 0.67
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And ARR Growth
The high recurring-revenue mix improves visibility and customer retention economics, while low-double-digit organic ARR growth indicates continued demand for Vitalhub’s healthcare workflow and care-management software.
Strong Balance Sheet And M&A Capacity
Minimal leverage and substantial liquidity reduce financial risk and give Vitalhub flexibility to fund product investment, pursue complementary acquisitions, and withstand variability in healthcare procurement cycles.
Improving Profitability And Integration Benefits
Improving EBITDA alongside completed integration work suggests that scale and acquisition synergies can support operating leverage. Strong gross margins and ongoing AI development may further expand software earnings power over time.
Bears Say
UK Contract And Regulatory Uncertainty
The NHS procurement outcome and related break clause could affect customer commitments, sales cycles, and ARR in the UK. This creates a durable execution risk because public-sector contract decisions can materially shape regional growth.
Moderating Growth And Modest Returns
Although Vitalhub remains profitable, slower reported growth and modest returns on equity indicate that the business is not yet converting its platform and balance-sheet advantages into consistently high shareholder returns.
Cash-Flow Volatility
Recent cash generation is encouraging, but the historical variability shows that implementation timing, working capital, and acquisition activity can disrupt conversion of accounting earnings into dependable free cash flow.
Vitalhub News
6OVA FAQ
What was Vitalhub’s price range in the past 12 months?
What is Vitalhub’s market cap?
When is Vitalhub’s upcoming earnings report date?
How were Vitalhub’s earnings last quarter?
Is Vitalhub overvalued?
Does Vitalhub pay dividends?
What is Vitalhub’s EPS estimate?
How many shares outstanding does Vitalhub have?
What happened to Vitalhub’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vitalhub?
What is the TipRanks Smart Score and how is it calculated?
Vitalhub Stock Smart Score
Company Description
Vitalhub
Vitalhub Corp., through its subsidiaries, provides innovative technological solutions to health and human service providers internationally, specifically catering to markets in Canada, the United States, the United Kingdom, Australia, and Western Asia. The company's diverse array of offerings comprises electronic healthcare records, case management systems, care coordination platforms, tools for optimizing patient flow and operational insights, and various mobile applications. Incorporated in 2010, Vitalhub is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Daniel Paul Matlow
- Employees
- 700
- Website
- vitalhub.com
- Address
- 480 University Avenue, Toronto, ON, M5G 1V2, CA
Vitalhub (6OVA) Earnings & Revenues
6OVA Earnings Call
Earnings Call SentimentPositive
The call presented multiple strong financial and operational positives: robust revenue growth (+33% YoY), exceeding the $100M ARR milestone (+10% organic ARR growth), improved adjusted EBITDA ($8.2M, +~30% YoY) and a healthy cash position (>$136M, no debt). Strategic progress includes near-complete integration of prior acquisitions, the Buddy Healthcare acquisition to expand digital patient engagement, active M&A pipeline, and ongoing AI product monetization efforts. The primary near-term headwinds are regional/regulatory uncertainty in the U.K. related to the Palantir/FTB situation that caused some suspended use and ARR reductions, modest gross margin compression (79% vs 81% prior year), and normal services revenue volatility. Overall, the highlights materially outweigh the lowlights, and the issues noted appear addressable or temporary.
View all DE:6OVA earnings summaries6OVA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 4 |
| Technical Analysis | 4 | 1 | 4 |
| Moving Averages | 12 | 0 | 0 |













